Department of Cardiology, Medical University Hospital Heidelberg, Heidelberg, Germany.
Br J Pharmacol. 2012 May;166(2):764-73. doi: 10.1111/j.1476-5381.2011.01813.x.
Two-pore-domain K(+) channels (K(2P) ) mediate K(+) background currents that modulate the membrane potential of excitable cells. K(2P) 18.1 (TWIK-related spinal cord K(+) channel) provides hyperpolarizing background currents in neurons. Recently, a dominant-negative loss-of-function mutation in K(2P) 18.1 has been implicated in migraine, and activation of K(2P) 18.1 channels was proposed as a therapeutic strategy. Here we elucidated the molecular mechanisms underlying PKC-dependent activation of K(2P) 18.1 currents.
Human K(2P) 18.1 channels were heterologously expressed in Xenopus laevis oocytes, and currents were recorded with the two-electrode voltage clamp technique.
Stimulation of PKC using phorbol 12-myristate-13-acetate (PMA) activated the hK(2P) 18.1 current by 3.1-fold in a concentration-dependent fashion. The inactive analogue 4α-PMA had no effect on channel activity. The specific PKC inhibitors bisindolylmaleimide I, Ro-32-0432 and chelerythrine reduced PMA-induced channel activation indicating that PKC is involved in this effect of PMA. Selective activation of conventional PKC isoforms with thymeleatoxin (100 nM) did not reproduce K(2P) 18.1 channel activation. Current activation by PMA was not affected by pretreatment with CsA (calcineurin inhibitor) or KT 5720 (PKA inhibitor), ruling out a significant contribution of calcineurin or cross-talk with PKA to the PKC-dependent hK(2P) 18.1 activation. Finally, mutation of putative PKC phosphorylation sites did not prevent PMA-induced K(2P) 18.1 channel activation.
We demonstrated that activation of hK(2P) 18.1 (TRESK) by PMA is mediated by PKC stimulation. Hence, PKC-mediated activation of K(2P) 18.1 background currents may serve as a novel molecular target for migraine treatment.
双孔域钾(K(+))通道(K(2P))介导调节可兴奋细胞膜电位的 K(+)背景电流。K(2P) 18.1(TWIK 相关脊髓 K(+)通道)为神经元提供超极化背景电流。最近,K(2P) 18.1 的显性负效失活突变与偏头痛有关,并且激活 K(2P) 18.1 通道被提出作为一种治疗策略。在这里,我们阐明了 PKC 依赖性激活 K(2P) 18.1 电流的分子机制。
将人 K(2P) 18.1 通道异源表达在非洲爪蟾卵母细胞中,并使用双电极电压钳技术记录电流。
使用佛波醇 12-肉豆蔻酸 13-乙酸酯(PMA)刺激 PKC 以浓度依赖性方式将 hK(2P) 18.1 电流激活 3.1 倍。无活性类似物 4α-PMA 对通道活性没有影响。特定的 PKC 抑制剂双吲哚马来酰亚胺 I、Ro-32-0432 和 Chelerythrine 降低了 PMA 诱导的通道激活,表明 PKC 参与了 PMA 的这种作用。用百里香醌(100 nM)选择性激活常规 PKC 同工型不能复制 K(2P) 18.1 通道激活。PMA 处理前用 CsA(钙调神经磷酸酶抑制剂)或 KT 5720(PKA 抑制剂)预处理不会影响电流激活,排除了钙调神经磷酸酶或与 PKA 的交叉对话对 PKC 依赖性 hK(2P) 18.1 激活的显著贡献。最后,假定的 PKC 磷酸化位点的突变不能阻止 PMA 诱导的 K(2P) 18.1 通道激活。
我们证明了 PMA 激活 hK(2P) 18.1(TRESK)是通过 PKC 刺激介导的。因此,PKC 介导的 K(2P) 18.1 背景电流激活可能成为偏头痛治疗的新分子靶点。